Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Baxter
Boehringer Ingelheim
Harvard Business School
Mallinckrodt

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

REZULIN Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Rezulin patents expire, and when can generic versions of Rezulin launch?

Rezulin is a drug marketed by Pfizer Pharms and is included in one NDA.

The generic ingredient in REZULIN is troglitazone. Additional details are available on the troglitazone profile page.

Drug patent expirations by year for REZULIN
Recent Clinical Trials for REZULIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
NovartisPhase 2

See all REZULIN clinical trials

Synonyms for REZULIN
(+-)-all-rac-5-(p-((6-Hydroxy-2,5,7,8-tetramethyl-2-chromanyl)methoxy)benzyl)-2,4-thiazolidinedione
(+/-)-5-[4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl]-2,4-thiazolidinedione
(5R)-5-[[4-[[(2S)-6-hydroxy-2,5,7,8-tetramethyl-chroman-2-yl]methoxy]phenyl]methyl]thiazolidine-2,4-dione
18524-EP2269989A1
18524-EP2270011A1
18524-EP2272825A2
18524-EP2272841A1
18524-EP2275414A1
18524-EP2295409A1
18524-EP2298742A1
18524-EP2301936A1
18524-EP2305219A1
18524-EP2305648A1
18524-EP2308847A1
18524-EP2314576A1
18524-EP2314588A1
2,4-Thiazolidinedione, 5-((4-((3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy)phenyl)methyl)-
2,4-thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-
2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]- (9CI)
2,4-thiazolidinedione,5-((4-((3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2h-1-b
2,4-Thiazolidinedione,5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-
322T877
5-(4-((6-hydroxy-2,5,7,8-tetramethylchroman-2-yl-methoxy)benzyl)-2,4-thiazolidinedione)
5-(4-((6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy)benzyl)thiazolidine-2,4-dione
5-(4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl)thiazolidine-2
5-(4-(6-Hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl)thiazolidine-2,4-dione
5-[(4-{[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methyl]oxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione
5-[[4-[(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1- benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazlidinedione
5-[[4-[(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione
5-[[4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
5-[[4-[(6-hydroxy-2,5,7,8-tetramethyl-chroman-2-yl)methoxy]phenyl]methyl]thiazolidine-2,4-dione
5-[[4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
5-[4-(6-Hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-1-benzopyran-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]-2,4-dioxothiazolidine
5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine -2,4-dione
5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
5-{4-(6-hydroxy-2, 5, 7, 8-tetramethylchroman-2-yl-methoxy) benzyl) thiazolidine-2,4-dione
5-{4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2h-chromen-2-yl)methoxy]benzyl}-1,3-thiazolidin-2,4-dion
5-{4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methoxy]benzyl}-1,3-thiazolidine-2,4-dione
97322-87-7
AB00643330-02
AB0125513
AC1L1KOT
AKOS000281116
AKOS024457434
AN-34774
API0004529
BC686826
BCP06753
BDBM50088494
BDBM50101974
BG0468
BRD-A13084692-001-02-5
BRN 4338399
C-22371
C24H27NO5S
CAS-97322-87-7
CC-35518
CCG-208125
CCRIS 8969
CHEBI:9753
CHEMBL3542292
CI 991
CI-991
ci991
CS 045
CS-045
CS-1634
CS045
CTK7H5564
D00395
DB00197
DSSTox_CID_3719
DSSTox_GSID_23719
DSSTox_RID_77162
DTXSID8023719
enzopyran-2-yl)methoxy)phenyl)methyl)-
FT-0630994
GP8940
GR 92132X
GR-92132X
GR92132X
GTPL2693
GXPHKUHSUJUWKP-UHFFFAOYSA-N
HMS2089D22
HMS2093D04
HMS3649G12
HMS3713D08
HSCI1_000037
HY-50935
I14-1977
K752
KB-81354
KS-00001DVG
LS-151313
MLS006010817
MolPort-003-666-725
NCGC00161599-01
NCGC00161599-02
NCGC00161599-03
NCGC00161599-04
NCGC00161599-05
NCGC00161599-06
NCGC00161599-07
NCGC00161599-08
NCGC00161599-09
NCGC00161599-11
NCGC00164445-01
NCGC00254440-01
Noscal
Prelay
Resulin
resulin(tm)
Rezulin (TN)
Romglizone
Romozin
s8432
SC-46000
SCHEMBL4959
SMP2_000224
SMR001550129
Spectrum5_001973
SR-05000000454
SR-05000000454-2
SR-05000000454-3
SR-05000000454-5
Tox21_112119
Tox21_112119_1
Tox21_300470
troglitazona
troglitazone
Troglitazone (CS-045)
Troglitazone (JAN/USAN/INN)
Troglitazone [USAN:BAN:INN]
Troglitazone [USAN:INN:BAN]
Troglitazone, >=98% (HPLC)
troglitazonum
UPCMLD-DP017
UPCMLD-DP017:001
UPCMLD-DP017:002
VA11909

US Patents and Regulatory Information for REZULIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer Pharms REZULIN troglitazone TABLET;ORAL 020720-001 Jan 29, 1997 DISCN No No   Start Trial   Start Trial   Start Trial
Pfizer Pharms REZULIN troglitazone TABLET;ORAL 020720-003 Aug 4, 1997 DISCN No No   Start Trial   Start Trial   Start Trial
Pfizer Pharms REZULIN troglitazone TABLET;ORAL 020720-002 Jan 29, 1997 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for REZULIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer Pharms REZULIN troglitazone TABLET;ORAL 020720-003 Aug 4, 1997   Start Trial   Start Trial
Pfizer Pharms REZULIN troglitazone TABLET;ORAL 020720-003 Aug 4, 1997   Start Trial   Start Trial
Pfizer Pharms REZULIN troglitazone TABLET;ORAL 020720-003 Aug 4, 1997   Start Trial   Start Trial
Pfizer Pharms REZULIN troglitazone TABLET;ORAL 020720-001 Jan 29, 1997   Start Trial   Start Trial
Pfizer Pharms REZULIN troglitazone TABLET;ORAL 020720-002 Jan 29, 1997   Start Trial   Start Trial
Pfizer Pharms REZULIN troglitazone TABLET;ORAL 020720-001 Jan 29, 1997   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Colorcon
McKinsey
Medtronic
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.